US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by CG Oncology Inc.

News headline image
CG Oncology to Present at Upcoming Investor Conferences in September
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology to Present at Upcoming Investor Conferences in June
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology to Present at Upcoming Investor Conferences in May
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Announces New Board Member and Board Transition
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Completes Enrollment in PIVOT-006
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
From CG Oncology Inc.
Via GlobeNewswire
Tickers ANIP CGON
News headline image
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
News headline image
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON